Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Retinoblastoma 1Neuroblastoma 1Glioma 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
racotumomab × Genitourinary × Clear all
NCT01598454 2015-07-29

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Laboratorio Elea Phoenix S.A.

Phase 1 Completed
15 enrolled
CNSGenitourinaryOther solid neoplasmSarcoma

Glioma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡